Seasonal influenza vaccine dose distribution in 195 countries (2004-2013): Little progress in estimated global vaccination coverage.

Seasonal influenza is an important disease which results in 250,000-500,000 annual deaths worldwide. Global targets for vaccination coverage rates (VCRs) in high-risk groups are at least 75% in adults ≥65 years and increased coverage in other risk groups. The International Federation of Pharmaceutical Manufacturers and Associations Influenza Vaccine Supply (IFPMA IVS) International Task Force developed a survey methodology in 2008, to assess the global distribution of influenza vaccine doses as a proxy for VCRs. This paper updates the previous survey results on absolute numbers of influenza vaccine doses distributed between 2004 and 2013 inclusive, and dose distribution rates per 1000 population, and provides a qualitative assessment of the principal enablers and barriers to seasonal influenza vaccination. The two main findings from the quantitative portion of the survey are the continued negative trend for dose distribution in the EURO region and the perpetuation of appreciable differences in scale of dose distribution between WHO regions, with no observed convergence in the rates of doses distributed per 1000 population over time. The main findings from the qualitative portion of the survey were that actively managing the vaccination program in real-time and ensuring political commitment to vaccination are important enablers of vaccination, whereas insufficient access to vaccination and lack of political commitment to seasonal influenza vaccination programs are likely contributing to vaccination target failures. In all regions of the world, seasonal influenza vaccination is underutilized as a public health tool. The survey provides evidence of lost opportunity to protect populations against potentially serious influenza-associated disease. We call on the national and international public health communities to re-evaluate their political commitment to the prevention of the annual influenza disease burden and to develop a systematic approach to improve vaccine distribution equitably.

[1]  F. Carrat,et al.  Trends in influenza vaccination behaviours--results from the CoPanFlu cohort, France, 2006 to 2011. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[2]  A. Palache.  Seasonal influenza vaccine provision in 157 countries (2004-2009) and the potential influence of national public health policies. , 2011, Vaccine.

[3]  A. Palache,et al.  Annual public health and economic benefits of seasonal influenza vaccination: a European estimate , 2014, BMC Public Health.

[4]  N. Andrews,et al.  Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis , 2013, BMJ : British Medical Journal.

[5]  T. Szucs,et al.  Increasing influenza vaccination coverage in recommended population groups in Europe , 2009, Expert review of vaccines.

[6]  Neill Nugent,et al.  The Council of the European Union , 2017 .

[7]  R. Rüttimann,et al.  Influenza among the elderly in the Americas: a consensus statement. , 2013, Revista panamericana de salud publica = Pan American journal of public health.

[8]  W. Roper,et al.  Prevention and control of influenza: Part I, Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 1994, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[9]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[10]  N. Cox,et al.  Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2006, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[11]  Roger I Glass,et al.  Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[12]  C. Bridges,et al.  Influenza Vaccination of Health-Care Personnel Recommendations of the Healthcare Infection Control Practices Advisory Committee ( HICPAC ) and the Advisory Committee on Immunization Practices ( ACIP ) , 2006 .

[13]  L. Grohskopf,et al.  Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) — United States, 2014–15 Influenza Season , 2014, MMWR. Morbidity and mortality weekly report.

[14]  S. Himanen,et al.  AS03 Adjuvanted AH1N1 Vaccine Associated with an Abrupt Increase in the Incidence of Childhood Narcolepsy in Finland , 2012, PloS one.

[15]  C. Stroud,et al.  The 2009 H1N1 Influenza Vaccination Campaign: summary of a workshop series. , 2010 .

[16]  J. Kaldor,et al.  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. , 2010, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[17]  P. Peretti-Watel,et al.  Dramatic change in public attitudes towards vaccination during the 2009 influenza A(H1N1) pandemic in France. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[18]  A. Palache,et al.  Seasonal influenza vaccine dose distribution in 157 countries (2004-2011). , 2014, Vaccine.

[19]  M. Kieny,et al.  Global production capacity of seasonal influenza vaccine in 2011. , 2013, Vaccine.

[20]  M. Schwenkglenks,et al.  Influenza vaccination coverage rates in five European countries during season 2006/07 and trends over six consecutive seasons , 2008, BMC public health.